Zibotentan (ZD4054) , ≥98% , 186497-07-4
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB639.20 | In Stock |
|
| 25MG | RMB2239.20 | In Stock |
|
| 100MG | RMB5599.20 | In Stock |
|
| 250MG | RMB10112.00 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 239 - 241°C |
| Boiling point: | 637.0±65.0 °C(Predicted) |
| Density | 1.422 |
| storage temp. | Sealed in dry,Store in freezer, under -20°C |
| solubility | DMSO (Sparingly), Methanol (Slightly) |
| form | Solid |
| pka | 5.62±0.40(Predicted) |
| color | White to Off-White |
| InChI | 1S/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25) |
| InChIKey | FJHHZXWJVIEFGJ-UHFFFAOYSA-N |
| SMILES | O=S(C1=C(C2=CC=C(C3=NN=CO3)C=C2)N=CC=C1)(NC4=NC=C(C)N=C4OC)=O |
Description and Uses
Zibotentan is a selective antagonist of the endothelin (ET) receptor type A (IC50s = 21 and >10,000 nM for human recombinant ETA and ETB, respectively). It inhibits growth of HEY, OVCA 433, SKOV3, and A2780 cells induced by endothelin 1 (ET-1; ) in vitro. Zibotentan reduces ET-1-induced expression of MMP-2, MMP-9, VEGF, COX-1 and COX-2, mediators of cell invasion and angiogenesis, in HEY cells. In vivo, zibotentan (10-50 mg/kg per day) reduces tumor growth in an HEY mouse xenograft model in a dose-dependent manner. Formulations containing zibotentan are under clinical investigation for the treatment of ovarian and castration-resistant prostate cancers.
Zibotentan is a specific endothelin-A receptor antagonist that is a potential candidate in the treatment of prostate cancer, bone metastasis and various other types of cancer.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P301+P312+P330 |
| WGK Germany | WGK 3 |
| Storage Class | 11 - Combustible Solids |
| Hazard Classifications | Acute Tox. 4 Oral |
